B2RNB2 (B2RNB2_HUMAN) Homo sapiens (Human)
ADAM metallopeptidase domain 18 UniProtKBInterProInteractive Modelling
824 aa; Sequence (Fasta) ;
3 identical sequences: Homo sapiens: P78536; Pan troglodytes: A0A2J8NM15; Pan paniscus: A0A2R9BL62
It is possible new templates exist for this target since these models were created.
Available Structures
28 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Structure of mature human ADAM17/iRhom2 sheddase complex in complex with ADAM17 prodomain |
Heteromer P78536; Q6PJF5; | 100 | 1×ZN; 1×CA; | |||
| Structure of human ADAM17/iRhom2 sheddase complex |
Heteromer P78536; Q6PJF5; | 100.0 | 1×ZN; 1×CA; | |||
| Crystal structure of the TACE-N-TIMP-3 complex |
Heteromer P35625; P78536; | 99.22 | 1×ZN; 1×NA; | |||
| Structure of mature human ADAM17/iRhom2 sheddase complex, conformation 2 |
Heteromer P78536; Q6PJF5; | 100 | 1×CA; | |||
| Structure of mature human ADAM17/iRhom2 sheddase complex, conformation 1 |
Heteromer P78536; Q6PJF5; | 100 | 1×CA; | |||
| Crystal structure of the PTPN3 PDZ domain bound to the PBM TACE C-terminal peptide |
Heteromer P26045; P78536; | 100 | 2×NA; | |||
| Crystal structure analysis 0f the TNF-a Coverting Enzyme (TACE) in complexed with Aryl-sulfonamide | monomer | 99.24 | 1×ZN; 1×283; | |||
| Crystal structure of TACE in complex with IK682 | monomer | 98.85 | 1×ZN; 1×541; | |||
| Crystal structure of catalytic domain of TACE with the first hydantoin inhibitor occupying the S1' … | monomer | 98.82 | 1×ZN; 1×724; | |||
| Novel thio-based TACE inhibitors Part 2: Rational design, synthesis and SAR of thiol-contaning aryl… | monomer | 99.23 | 2×ZN; 1×440; | |||
| Crystal structure of catalytic domain of TNF-alpha converting enzyme (TACE) with inhibitor | monomer | 99.23 | 1×ZN; 1×IH6; | |||
| Crystal structure of catalytic domain of TACE with Thiomorpholine Sulfonamide Hydroxamate inhibitor | monomer | 99.23 | 1×ZN; 1×4NH; | |||
| Crystal structure of catalytic domain of TACE with carboxylate inhibitor | monomer | 98.82 | 1×ZN; 1×INN; | |||
| Crystal structure of catalytic domain of TACE with 2-(2-Aminothiazol-4-yl)pyrrolidine-Based Tartrat… | monomer | 98.81 | 1×IPA; 1×INN; 1×ZN; 1×CA; | |||
| Crystal structure of catalytic domain of TACE with hydroxamate inhibitor | monomer | 98.84 | 1×ZN; 1×INN; 1×CIT; | |||
| Crystal structure of the catalytic domain of TACE with Isoindolinone-biphenyl-hydantoin inhibitor | monomer | 98.84 | 1×Z93; 1×ZN; | |||
| Crystal structure of TACE in complex with JMV 390-1 | monomer | 98.82 | 1×ZN; 1×INN; | |||
| Crystal structure of TACE in complex with TAPI-2 | monomer | 98.81 | 1×ZN; 1×CA; 1×INN; 1×IPA; | |||
| Crystal structure of catalytic domain of TACE with tartrate-based inhibitor | monomer | 98.82 | 1×ZN; 1×INN; | |||
| Crystal structure of catalytic domain of TACE with phenyl-pyrrolidinyl-tartrate inhibitor | monomer | 98.81 | 1×ZN; 1×INN; 1×IPA; | |||
| Crystal structure of the catalytic domain of TACE with Indazolinone-phenyl-hydantoin inhibitor | monomer | 98.81 | 1×ZN; 1×727; 1×IPA; | |||
| Crystal structure of catalytic domain of TACE with hydroxamate inhibitor | monomer | 98.81 | 1×ZN; 1×615; 1×INN; | |||
| Crystal structure of catalytic domain of tace with benzimidazolyl-thienyl-tartrate based inhibitor | monomer | 98.81 | 1×ZN; 1×50X; | |||
| Crystal structure of catalytic domain of TACE with hydantoin inhibitor | monomer | 98.82 | 1×ZN; 1×INN; 1×IPA; | |||
| Crystal structure of catalytic domain of TACE with inhibitor | monomer | 99.22 | 1×ZN; 1×INN; | |||
| CATALYTIC DOMAIN OF TNF-ALPHA CONVERTING ENZYME (TACE) | monomer | 99.22 | 1×ZN; 1×INN; | |||
| Crystal Structure of TACE with Tryptophan Sulfonamide Derivative Inhibitor | monomer | 99.21 | 1×792; 1×ZN; | |||
| The membran-proximal domain of ADAM17 | monomer | 100 | ||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8snl.1.A | monomer | 0.78 | 1×ZN; 1×CA; | 100.00 | ||